Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Pulse Biosciences, Inc. (“Pulse” or the “Company”) (NASDAQ: PLSE) investors concerning the Company and its officers’ possible violations of federal securities laws. To obtain information or aid in the investigation, please visit the Pulse investigation page on our website at www.glancylaw.com/case/pulse-biosciences-inc.

On September 11, 2017, Pulse announced that it withdrew its application to the FDA for 510(k) clearance of its PulseTx System. The Company further stated that the withdrawal was the result of “the FDA’s appropriate request for additional data that could not be provided within the Agency’s 90-day review period that would have otherwise ended on September 10, 2017.”

On this news, shares of Pulse fell more than 14% during intraday trading on September 11, 2017, thereby damaging investors.

Follow us for updates on Twitter: twitter.com/GPM_LLP.

If you purchased Pulse securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170911006127/en/